Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine

E. Wagner, WG. Honer, IE. Sommer, S. Koops, DM. Blumberger, ZJ. Daskalakis, JJ. Dlabac-De Lange, L. Bais, H. Knegtering, A. Aleman, T. Novak, M. Klirova, C. Slotema, J. Brunelin, E. Poulet, M. Kujovic, J. Cordes, T. Wobrock, D. Siskind, P....

. 2021 ; 22 (1) : 14-26. [pub] 20200313

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019604

OBJECTIVES: Biological strategies to improve treatment efficacy in clozapine-treated patients are urgently needed. Repetitive transcranial magnetic stimulation (rTMS) merits consideration as intervention for patients with persistent auditory hallucinations (AH) or negative symptoms (NS) not responding sufficiently to clozapine treatment. METHODS: Data from 10 international RCTs of rTMS for patients being treated with clozapine were pooled. Two levels of symptomatic response were defined: improvement of ≥20% and ≥50% on study-specific primary endpoint scales. Changes in the positive and negative syndrome scale (PANSS) from baseline to endpoint assessment were also analysed. RESULTS: Analyses of 131 patients did not reveal a significant difference for ≥20% and ≥50% response thresholds for improvement of AH, negative or total symptoms between active and sham rTMS groups. The number needed to treat (NNT) for an improvement in persistent AH was nine following active rTMS. PANSS scores did not improve significantly from baseline to endpoint between active and sham groups in studies investigating NS and AH. CONCLUSIONS: rTMS as a treatment for persistent symptoms in clozapine-treated patients did not show a beneficial effect of active compared to sham treatment. For AH, the size of the NNTs indicates a possible beneficial effect of rTMS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019604
003      
CZ-PrNML
005      
20210830101205.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/15622975.2020.1733080 $2 doi
035    __
$a (PubMed)32081071
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Wagner, Elias $u Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
245    10
$a Repetitive transcranial magnetic stimulation (rTMS) for schizophrenia patients treated with clozapine / $c E. Wagner, WG. Honer, IE. Sommer, S. Koops, DM. Blumberger, ZJ. Daskalakis, JJ. Dlabac-De Lange, L. Bais, H. Knegtering, A. Aleman, T. Novak, M. Klirova, C. Slotema, J. Brunelin, E. Poulet, M. Kujovic, J. Cordes, T. Wobrock, D. Siskind, P. Falkai, T. Schneider-Axmann, A. Hasan
520    9_
$a OBJECTIVES: Biological strategies to improve treatment efficacy in clozapine-treated patients are urgently needed. Repetitive transcranial magnetic stimulation (rTMS) merits consideration as intervention for patients with persistent auditory hallucinations (AH) or negative symptoms (NS) not responding sufficiently to clozapine treatment. METHODS: Data from 10 international RCTs of rTMS for patients being treated with clozapine were pooled. Two levels of symptomatic response were defined: improvement of ≥20% and ≥50% on study-specific primary endpoint scales. Changes in the positive and negative syndrome scale (PANSS) from baseline to endpoint assessment were also analysed. RESULTS: Analyses of 131 patients did not reveal a significant difference for ≥20% and ≥50% response thresholds for improvement of AH, negative or total symptoms between active and sham rTMS groups. The number needed to treat (NNT) for an improvement in persistent AH was nine following active rTMS. PANSS scores did not improve significantly from baseline to endpoint between active and sham groups in studies investigating NS and AH. CONCLUSIONS: rTMS as a treatment for persistent symptoms in clozapine-treated patients did not show a beneficial effect of active compared to sham treatment. For AH, the size of the NNTs indicates a possible beneficial effect of rTMS.
650    12
$a klozapin $7 D003024
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a halucinace $x terapie $7 D006212
650    _2
$a lidé $7 D006801
650    12
$a schizofrenie $x farmakoterapie $7 D012559
650    _2
$a schizofrenie (psychologie) $7 D012565
650    _2
$a transkraniální magnetická stimulace $7 D050781
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Honer, William G $u Department of Psychiatry, The University of British Columbia, Vancouver, Canada
700    1_
$a Sommer, Iris E $u Department of Biomedical Sciences of Cells and Systems, Section Cognitive Neuropsychology, University Medical Center Groningen, Groningen, the Netherlands
700    1_
$a Koops, Sanne $u Department of Psychiatry, University Medical Center Utrecht, Utrecht, the Netherlands
700    1_
$a Blumberger, Daniel M $u Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Canada $u Campbell Family Research Institute, Centre for Addiction and Mental Health, Toronto, Canada $u Department of Psychiatry, University of Toronto, Toronto, Canada
700    1_
$a Daskalakis, Zafiris J $u Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Canada $u Campbell Family Research Institute, Centre for Addiction and Mental Health, Toronto, Canada $u Department of Psychiatry, University of Toronto, Toronto, Canada
700    1_
$a Dlabac-De Lange, Jozarni J $u Lentis Psychiatric Institute, Groningen, the Netherlands $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
700    1_
$a Bais, Leonie $u Lentis Psychiatric Institute, Groningen, the Netherlands
700    1_
$a Knegtering, Henderikus $u Lentis Psychiatric Institute, Groningen, the Netherlands $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
700    1_
$a Aleman, André $u Lentis Psychiatric Institute, Groningen, the Netherlands $u University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
700    1_
$a Novak, Tomas $u Klecany and Third Faculty of Medicine, Charles University, National Institute of Mental Health, Prague, Czech Republic
700    1_
$a Klirova, Monika $u Klecany and Third Faculty of Medicine, Charles University, National Institute of Mental Health, Prague, Czech Republic
700    1_
$a Slotema, Christina $u Department of Personality Disorders, Parnassia Psychiatric Institute, the Hague, Netherlands
700    1_
$a Brunelin, Jerome $u INSERM U1028, CNRS UMR 5292, CRNL, Centre Hospitalier Le Vinatier, Bron, France
700    1_
$a Poulet, Emmanuel $u INSERM U1028, CNRS UMR 5292, CRNL, Centre Hospitalier Le Vinatier, Bron, France
700    1_
$a Kujovic, Milenko $u Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University Hospital, Düsseldorf, Germany
700    1_
$a Cordes, Joachim $u Department of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University Hospital, Düsseldorf, Germany
700    1_
$a Wobrock, Thomas $u Department of Psychiatry and Psychotherapy, Georg-August-University, Goettingen, Germany $u Centre of Mental Health, County Hospitals Darmstadt-Dieburg, Groß-Umstadt, Germany
700    1_
$a Siskind, Dan $u School of Medicine, University of Queensland, Brisbane, Australia $u Metro South Addiction and Mental Health Service, Brisbane, Australia
700    1_
$a Falkai, Peter $u Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
700    1_
$a Schneider-Axmann, Thomas $u Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
700    1_
$a Hasan, Alkomiet $u Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany
773    0_
$w MED00176986 $t The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry $x 1814-1412 $g Roč. 22, č. 1 (2021), s. 14-26
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32081071 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101206 $b ABA008
999    __
$a ok $b bmc $g 1690433 $s 1140050
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 1 $d 14-26 $e 20200313 $i 1814-1412 $m The world journal of biological psychiatry $n World J Biol Psychiatry $x MED00176986
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace